Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies

Br J Haematol. 2007 Mar;136(6):829-32. doi: 10.1111/j.1365-2141.2007.06512.x.

Abstract

Epigenetic silencing of tumour suppressor genes (TSG) inactivates TSG functions. Previously, we identified PCDH10 as a methylated TSG in carcinomas. Here, we detected its frequent silencing and methylation in lymphoma cell lines including 100% Burkitt, 100% diffuse large B cell, 86% Hodgkin, 100% nasal natural killer/T-cell lymphoma and 1/3 of leukaemia cell lines, and in primary tumours but not in normal peripheral blood mononuclear cells or lymph nodes. PCDH10 silencing could be reversed by demethylation with 5-aza-2'-deoxycytidine. Methylation was further detected in 14% of Hodgkin lymphoma sera. Thus, PCDH10 methylation is frequently involved in lymphomagenesis and could serve as a tumour-specific biomarker.

MeSH terms

  • Biomarkers, Tumor*
  • Burkitt Lymphoma / genetics
  • Cadherins / genetics*
  • Cell Line, Tumor
  • CpG Islands
  • DNA Methylation
  • Epigenesis, Genetic*
  • Gene Expression Regulation, Neoplastic*
  • Gene Silencing
  • Hematologic Neoplasms / genetics*
  • Hodgkin Disease / genetics
  • Humans
  • Leukemia / genetics
  • Lymphoma, Large B-Cell, Diffuse / genetics
  • Lymphoma, T-Cell / genetics
  • Reverse Transcriptase Polymerase Chain Reaction

Substances

  • Biomarkers, Tumor
  • Cadherins
  • PCDH10 protein, human